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Existing somatostatin-based radiotracers (e.g. 111In-DOTA
TOC) have sole affinity for somatostatin receptor subtype 2
(sst2). This represents a drawback, given that sst1–5 have
been shown to be over-expressed in different tumours,
alone or concomitantly [1]. Our goal, therefore, was to de-
velop radiopeptides with broader receptor subtype profiles.
68Ga-DOTANOC is a first compound for PET imaging
with high affinity for sst2 and sst5 [2]. Its affinity profile
(IC50 nM) for human sst1–5 is, respectively, >10,000, 1.9±
0.4, 40±5.8, 260±74 and 7.2±1.6. For comparison, the
values for the standard compound, 111In-DOTATOC, are
>10,000, 4.6±0.2, 120±26, 230±82 and 130±17.
Here we present the 60 min p.i. 68Ga-DOTANOC PET
images and the 21 h p.i. 111In-DOTATOC planar images
of a 52-year-old patient with an advanced neuroendocrine
tumour. The two examinations were performed within
4 weeks. During this time interval the patient received
bisphosphonates.
Preparation and application of 68Ga-DOTANOC PET
and 68Ga-DOTATOC PET are comparable [3].
In the reported case study, the 68Ga-DOTANOC PET
scan shows high radioligand uptake in the liver and bone
metastases. Although many bone metastases appeared vi-
sually similar in the two scans, the right sixth rib and left
occipital bone metastases (arrows) are much more visible
on the 68Ga-DOTANOC PET scan. This selective differ-
ence cannot be explained simply by the advantages of the
PET technique. The possible predominance of sst5 in these
two bone metastases and the high sst5 affinity of
68Ga-
DOTANOC are in fact the probable reasons for the high
68Ga-DOTANOC and low 111In-DOTATOC uptake. The en-
larged liver and somatostatin receptor-positive organs such
as the spleen (high uptake) and pituitary gland and thyroid
(moderate uptake) are also visible. These normal organs,
known to express more sst than just sst2, are better visu-
alised with 68Ga-DOTANOC (see in particular the spleen).
We conclude that 68Ga-DOTANOC is an excellent can-
didate for primary diagnostic and follow-up investigations
in patients with suspected or proven somatostatin receptor-
positive tumours. Furthermore, in this case, predictive im-
aging indicates that 90Y- or 177Lu-DOTANOC has greater
potential for treatment of this patient than 90Y- or 177Lu-
DOTATOC.
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